I had guessed that January's drop was connected to Illumina's announcement in the same month, so was surprised that it reversed in April.
-
-
My guess (and it's really just a guess) is that they are ignoring the X Ten in figuring the prices. Illumina has been raising prices on their sequencing kits every April 1st, so that little bump makes sense. However, I'm not sure that they're taking into account the release of the v4 chemistry for the HiSeq 2500. That reduced the list price for 1Gb of sequence from $43 down to $29. (For comparison, it's just $7/Gb for the HiSeq X.)Originally posted by xyzzy123 View PostComment
-
https://www.genome.gov/sequencingcosts/ is no longer being updated. It looks like they hit the end of the graph and don't want to extend it. In any case, since the price is now dropping much more _slowly_ than Moore's Law, in another 10 years or so at this rate Moore's Law will catch up and the graph would look kind of silly.Comment
-
NOW there's finally a sizable drop.
The last two entries in the .xlsx file show a cost per genome of $4,211 on Apr. 15 and $1,363 on Jul. 15. I guess they decided to take the X Ten into account.Comment
-
Due to all the artificial limitations on the X10, I don't consider it an accurate reflection of real sequencing costs.Comment
-
Indeed. Those costs are misleading. There should be all sorts of asterisks detailing the assumptions. Might as well throw in the higher per-base cost of using PacBio to complete a genome.Originally posted by Brian Bushnell View Post
I've always hated that graph because of the misapplication of "Moore's Law". Stupid. But I have seen it in so many presentations that I just grit my teeth.Comment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment